Berkeley Heights, New Jersey — November 24, 2025 — Leads & Copy —
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) will present at the upcoming Noble Capital Markets 21st Annual Emerging Growth Equity Conference, the company announced today.
The presentation details are as follows:
- Type: Company presentation
- Speakers: Matthew Feinsod, Chief Medical Officer
- Date: Wednesday, December 3, 2025
- Time: 11:30 – 11:55 am ET
- Location: Florida Atlantic University, Boca Raton, FL
Kalaris management will also be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. The company was founded by Dr. Napoleone Ferrara, whose research led to anti-VEGF therapy development, and is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
cdavis@lifesciadvisors.com
ir@kalaristx.com
Source: Kalaris Therapeutics
